A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis (NCT05646381)
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.
Who can join: Review the eligibility criteria below.
Location: Heart Center Research Llc — Huntsville, Alabama
Age range: 50 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (140 Sites)
Showing the first 25 of 140 sites.
- Heart Center Research Llc — Huntsville, Alabama
- Cardiovascular Res Found — Beverly Hills, California
- National Heart Institute — Beverly Hills, California
- Flourish Clinical Resrch Covin — Covina, California
- Valley Clinical Trials — Northridge, California
- Stanford University Medical Center — Palo Alto, California
- University Of California San Diego — San Diego, California
- UC San Francisco Medical Center — San Francisco, California
- Excel Medical Clinical Trials LLC — Boca Raton, Florida
- Nova Clinical Research LLC — Bradenton, Florida
- Flourish Res Acq LLC North Miami — Miami, Florida
- Inpatient Research Clinical LLC — Miami Lakes, Florida
- Advanced Research for Health Improvement LLC — Naples, Florida
- Midwest Heart and Vascular Spec — Overland Park, Kansas
- Tufts Medical Center — Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts
- Brigham and Womens Hosp Harvard Med School — Boston, Massachusetts
- Brigham and Womens Hosp Harvard Med School — Boston, Massachusetts
- Henry Ford Hospital — Detroit, Michigan
- Henry Ford Hospital — Detroit, Michigan
- AA Medical Research Center — Flint, Michigan
- William Beaumont Hospital — Royal Oak, Michigan
- Minneapolis Heart Institute — Minneapolis, Minnesota
- University Of Minnesota — Minneapolis, Minnesota
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Aortic Stenosis
- PERIGON Pivotal Trial — Los Angeles, California
- ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement — Birmingham, Alabama
- PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis — Birmingham, Alabama
- Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study — Tucson, Arizona
- Application of TAVI at Experienced Interventional Cardiac Centers Without On-site Cardiac Surgery (ATLAS Study) — Edmonton, Alberta
- Systematic Ambulatory ECG Monitoring Following TAVI — Québec, Quebec
Explore by condition: All Aortic Stenosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.